ID   F263_HUMAN              Reviewed;         520 AA.
AC   Q16875; B7Z955; O43622; O75902; Q5VX15; Q5VX18; Q5VX19;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JUN-2023, entry version 216.
DE   RecName: Full=6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3;
DE            Short=6PF-2-K/Fru-2,6-P2ase 3;
DE            Short=PFK/FBPase 3;
DE   AltName: Full=6PF-2-K/Fru-2,6-P2ase brain/placenta-type isozyme;
DE   AltName: Full=Renal carcinoma antigen NY-REN-56;
DE   AltName: Full=iPFK-2;
DE   Includes:
DE     RecName: Full=6-phosphofructo-2-kinase;
DE              EC=2.7.1.105 {ECO:0000269|PubMed:10077634, ECO:0000269|PubMed:17499765, ECO:0000305|PubMed:16316985, ECO:0000305|PubMed:22275052};
DE   Includes:
DE     RecName: Full=Fructose-2,6-bisphosphatase;
DE              EC=3.1.3.46 {ECO:0000305|PubMed:16316985, ECO:0000305|PubMed:17499765, ECO:0000305|PubMed:22275052};
GN   Name=PFKFB3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=8830046; DOI=10.1093/oxfordjournals.jbchem.a021270;
RA   Sakai A., Kato M., Fukasawa M., Ishiguro M., Furuya E., Sakakibara R.;
RT   "Cloning of cDNA encoding for a novel isozyme of fructose 6-phosphate, 2-
RT   kinase/fructose 2,6-bisphosphatase from human placenta.";
RL   J. Biochem. 119:506-511(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9146922; DOI=10.1023/a:1018482511456;
RA   Nicholl J., Hamilton J.A., Sutherland G.R., Sutherland R.L., Watts C.K.;
RT   "The third human isoform of 6-phosphofructo-2-kinase/fructose-2,6-
RT   bisphosphatase (PFKFB3) map position 10p14-p15.";
RL   Chromosome Res. 5:150-150(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10072580; DOI=10.1159/000015181;
RA   Manzano A., Rosa J.L., Ventura F., Perez J.X., Nadal M., Estivill X.,
RA   Ambrosio S., Gil J., Bartrons R.;
RT   "Molecular cloning, expression, and chromosomal localization of a
RT   ubiquitously expressed human 6-phosphofructo-2-kinase/ fructose-2, 6-
RT   bisphosphatase gene (PFKFB3).";
RL   Cytogenet. Cell Genet. 83:214-217(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   El-Maghrabi M.R.;
RT   "Human brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.";
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND CATALYTIC ACTIVITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=10077634; DOI=10.1073/pnas.96.6.3047;
RA   Chesney J., Mitchell R.A., Benigni F., Bacher M., Spiegel L., Al-Abed Y.,
RA   Han J.H., Metz C., Bucala R.;
RT   "An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich
RT   instability element: role in tumor cell glycolysis and the Warburg
RT   effect.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3047-3052(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [11]
RP   PHOSPHORYLATION AT SER-461.
RX   PubMed=12065600; DOI=10.1074/jbc.m205213200;
RA   Marsin A.S., Bouzin C., Bertrand L., Hue L.;
RT   "The stimulation of glycolysis by hypoxia in activated monocytes is
RT   mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-
RT   kinase.";
RL   J. Biol. Chem. 277:30778-30783(2002).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461; THR-463 AND SER-467, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461 AND SER-467, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461 AND SER-467, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   INTERACTION WITH PFKFB2.
RX   PubMed=36402789; DOI=10.1038/s41467-022-34907-0;
RA   McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y.,
RA   Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A.,
RA   Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E.,
RA   Garcia-Patos V., Recio J.A.;
RT   "BRAF activation by metabolic stress promotes glycolysis sensitizing
RT   NRASQ61-mutated melanomas to targeted therapy.";
RL   Nat. Commun. 13:7113-7113(2022).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH ADP AND FRUCTOSE
RP   6-PHOSPHATE, SUBUNIT, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=16316985; DOI=10.1074/jbc.m511019200;
RA   Kim S.G., Manes N.P., El-Maghrabi M.R., Lee Y.H.;
RT   "Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-
RT   kinase/fructose-2,6-bisphosphatase (PFKFB3): a possible new target for
RT   cancer therapy.";
RL   J. Biol. Chem. 281:2939-2944(2006).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) IN COMPLEXES WITH ADP; ATP; FRUCTOSE
RP   6-PHOSPHATE; FRUCTOSE-2,6-BISPHOSPHATE AND PHOSPHOENOLPYRUVATE, FUNCTION,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF
RP   ALA-45 AND LYS-169.
RX   PubMed=17499765; DOI=10.1016/j.jmb.2007.03.038;
RA   Kim S.G., Cavalier M., El-Maghrabi M.R., Lee Y.H.;
RT   "A direct substrate-substrate interaction found in the kinase domain of the
RT   bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-
RT   bisphosphatase.";
RL   J. Mol. Biol. 370:14-26(2007).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS), ACTIVE SITE, FUNCTION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=22275052; DOI=10.1002/prot.24015;
RA   Cavalier M.C., Kim S.G., Neau D., Lee Y.H.;
RT   "Molecular basis of the fructose-2,6-bisphosphatase reaction of PFKFB3:
RT   transition state and the C-terminal function.";
RL   Proteins 80:1143-1153(2012).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.03 ANGSTROMS) IN COMPLEX WITH
RP   FRUCTOSE-2,6-BISPHOSPHATE.
RX   PubMed=25849762; DOI=10.1021/acs.jmedchem.5b00352;
RA   Boyd S., Brookfield J.L., Critchlow S.E., Cumming I.A., Curtis N.J.,
RA   Debreczeni J., Degorce S.L., Donald C., Evans N.J., Groombridge S.,
RA   Hopcroft P., Jones N.P., Kettle J.G., Lamont S., Lewis H.J., MacFaull P.,
RA   McLoughlin S.B., Rigoreau L.J., Smith J.M., St-Gallay S., Stock J.K.,
RA   Turnbull A.P., Wheatley E.R., Winter J., Wingfield J.;
RT   "Structure-based design of potent and selective inhibitors of the metabolic
RT   kinase PFKFB3.";
RL   J. Med. Chem. 58:3611-3625(2015).
CC   -!- FUNCTION: Catalyzes both the synthesis and degradation of fructose 2,6-
CC       bisphosphate. {ECO:0000269|PubMed:10077634,
CC       ECO:0000269|PubMed:17499765, ECO:0000305|PubMed:16316985}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=beta-D-fructose 2,6-bisphosphate + H2O = beta-D-fructose 6-
CC         phosphate + phosphate; Xref=Rhea:RHEA:17289, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:57634, ChEBI:CHEBI:58579; EC=3.1.3.46;
CC         Evidence={ECO:0000305|PubMed:16316985, ECO:0000305|PubMed:17499765,
CC         ECO:0000305|PubMed:22275052};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17290;
CC         Evidence={ECO:0000305|PubMed:16316985};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + beta-D-fructose 6-phosphate = ADP + beta-D-fructose 2,6-
CC         bisphosphate + H(+); Xref=Rhea:RHEA:15653, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:57634, ChEBI:CHEBI:58579,
CC         ChEBI:CHEBI:456216; EC=2.7.1.105;
CC         Evidence={ECO:0000269|PubMed:10077634, ECO:0000269|PubMed:17499765,
CC         ECO:0000305|PubMed:16316985};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15654;
CC         Evidence={ECO:0000305|PubMed:10077634};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=10.2 uM for fructose 6-phosphate {ECO:0000269|PubMed:17499765};
CC         KM=16.9 uM for ATP {ECO:0000269|PubMed:17499765};
CC   -!- SUBUNIT: Homodimer (PubMed:16316985). Forms a heterodimer with PFKFB2
CC       (PubMed:36402789). {ECO:0000269|PubMed:16316985,
CC       ECO:0000269|PubMed:36402789}.
CC   -!- INTERACTION:
CC       Q16875; P16118: PFKFB1; NbExp=3; IntAct=EBI-764464, EBI-709807;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q16875-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16875-2; Sequence=VSP_004680;
CC       Name=3;
CC         IsoId=Q16875-3; Sequence=VSP_047165;
CC       Name=4;
CC         IsoId=Q16875-4; Sequence=VSP_054549;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Phosphorylation by AMPK stimulates activity.
CC       {ECO:0000269|PubMed:12065600}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the phosphoglycerate
CC       mutase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D49817; BAA08624.1; -; mRNA.
DR   EMBL; L77662; AAL40083.1; -; mRNA.
DR   EMBL; AF109735; AAD08818.1; -; mRNA.
DR   EMBL; AF041831; AAB99795.1; -; Genomic_DNA.
DR   EMBL; AF041823; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF041824; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF041825; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF041826; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF041827; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF041828; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF041829; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF041830; AAB99795.1; JOINED; Genomic_DNA.
DR   EMBL; AF056320; AAC62000.1; -; mRNA.
DR   EMBL; AK291263; BAF83952.1; -; mRNA.
DR   EMBL; AK304450; BAH14191.1; -; mRNA.
DR   EMBL; AL359960; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL157395; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86398.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86399.1; -; Genomic_DNA.
DR   EMBL; BC040482; AAH40482.1; -; mRNA.
DR   CCDS; CCDS44353.1; -. [Q16875-3]
DR   CCDS; CCDS60479.1; -. [Q16875-4]
DR   CCDS; CCDS7078.1; -. [Q16875-1]
DR   CCDS; CCDS81439.1; -. [Q16875-2]
DR   PIR; JC4626; JC4626.
DR   RefSeq; NP_001269559.1; NM_001282630.2. [Q16875-4]
DR   RefSeq; NP_001300992.1; NM_001314063.1. [Q16875-2]
DR   RefSeq; NP_004557.1; NM_004566.3. [Q16875-1]
DR   PDB; 2AXN; X-ray; 2.10 A; A=1-520.
DR   PDB; 2DWO; X-ray; 2.25 A; A=1-520.
DR   PDB; 2DWP; X-ray; 2.70 A; A=1-520.
DR   PDB; 2I1V; X-ray; 2.50 A; B=1-520.
DR   PDB; 3QPU; X-ray; 2.30 A; A=1-520.
DR   PDB; 3QPV; X-ray; 2.50 A; A=1-520.
DR   PDB; 3QPW; X-ray; 2.25 A; A=1-520.
DR   PDB; 4D4J; X-ray; 3.00 A; A=1-449.
DR   PDB; 4D4K; X-ray; 3.24 A; A=1-449.
DR   PDB; 4D4L; X-ray; 3.16 A; A=1-449.
DR   PDB; 4D4M; X-ray; 2.32 A; A=1-449.
DR   PDB; 4MA4; X-ray; 2.23 A; A=1-520.
DR   PDB; 5AJV; X-ray; 3.01 A; B=1-520.
DR   PDB; 5AJW; X-ray; 2.50 A; A=1-520.
DR   PDB; 5AJX; X-ray; 2.58 A; A=1-520.
DR   PDB; 5AJY; X-ray; 2.37 A; A=1-520.
DR   PDB; 5AJZ; X-ray; 2.35 A; A=1-520.
DR   PDB; 5AK0; X-ray; 2.03 A; A=1-520.
DR   PDB; 6ETJ; X-ray; 2.51 A; A=1-520.
DR   PDB; 6HVH; X-ray; 2.36 A; A=1-520.
DR   PDB; 6HVI; X-ray; 1.96 A; A=1-520.
DR   PDB; 6HVJ; X-ray; 2.28 A; A=1-520.
DR   PDB; 6IBX; X-ray; 2.11 A; A=4-447.
DR   PDB; 6IBY; X-ray; 2.51 A; A=4-447.
DR   PDB; 6IBZ; X-ray; 2.44 A; A=4-447.
DR   PDB; 6IC0; X-ray; 2.60 A; A=4-446.
DR   PDBsum; 2AXN; -.
DR   PDBsum; 2DWO; -.
DR   PDBsum; 2DWP; -.
DR   PDBsum; 2I1V; -.
DR   PDBsum; 3QPU; -.
DR   PDBsum; 3QPV; -.
DR   PDBsum; 3QPW; -.
DR   PDBsum; 4D4J; -.
DR   PDBsum; 4D4K; -.
DR   PDBsum; 4D4L; -.
DR   PDBsum; 4D4M; -.
DR   PDBsum; 4MA4; -.
DR   PDBsum; 5AJV; -.
DR   PDBsum; 5AJW; -.
DR   PDBsum; 5AJX; -.
DR   PDBsum; 5AJY; -.
DR   PDBsum; 5AJZ; -.
DR   PDBsum; 5AK0; -.
DR   PDBsum; 6ETJ; -.
DR   PDBsum; 6HVH; -.
DR   PDBsum; 6HVI; -.
DR   PDBsum; 6HVJ; -.
DR   PDBsum; 6IBX; -.
DR   PDBsum; 6IBY; -.
DR   PDBsum; 6IBZ; -.
DR   PDBsum; 6IC0; -.
DR   AlphaFoldDB; Q16875; -.
DR   SMR; Q16875; -.
DR   BioGRID; 111230; 63.
DR   ComplexPortal; CPX-1995; 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 complex.
DR   DIP; DIP-33964N; -.
DR   IntAct; Q16875; 28.
DR   MINT; Q16875; -.
DR   STRING; 9606.ENSP00000443319; -.
DR   BindingDB; Q16875; -.
DR   ChEMBL; CHEMBL2331053; -.
DR   GuidetoPHARMACOLOGY; 2937; -.
DR   DEPOD; PFKFB3; -.
DR   GlyCosmos; Q16875; 2 sites, 1 glycan.
DR   GlyGen; Q16875; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q16875; -.
DR   PhosphoSitePlus; Q16875; -.
DR   BioMuta; PFKFB3; -.
DR   DMDM; 3023733; -.
DR   EPD; Q16875; -.
DR   jPOST; Q16875; -.
DR   MassIVE; Q16875; -.
DR   MaxQB; Q16875; -.
DR   PaxDb; Q16875; -.
DR   PeptideAtlas; Q16875; -.
DR   ProteomicsDB; 61114; -. [Q16875-1]
DR   ProteomicsDB; 61115; -. [Q16875-2]
DR   ProteomicsDB; 65570; -.
DR   ProteomicsDB; 7006; -.
DR   Antibodypedia; 10861; 394 antibodies from 38 providers.
DR   DNASU; 5209; -.
DR   Ensembl; ENST00000360521.7; ENSP00000353712.2; ENSG00000170525.21. [Q16875-2]
DR   Ensembl; ENST00000379775.9; ENSP00000369100.4; ENSG00000170525.21. [Q16875-1]
DR   Ensembl; ENST00000379789.8; ENSP00000369115.4; ENSG00000170525.21. [Q16875-3]
DR   Ensembl; ENST00000536985.6; ENSP00000443319.2; ENSG00000170525.21. [Q16875-4]
DR   GeneID; 5209; -.
DR   KEGG; hsa:5209; -.
DR   MANE-Select; ENST00000379775.9; ENSP00000369100.4; NM_004566.4; NP_004557.1.
DR   UCSC; uc001ijd.4; human. [Q16875-1]
DR   AGR; HGNC:8874; -.
DR   CTD; 5209; -.
DR   DisGeNET; 5209; -.
DR   GeneCards; PFKFB3; -.
DR   HGNC; HGNC:8874; PFKFB3.
DR   HPA; ENSG00000170525; Tissue enhanced (adipose tissue, skeletal muscle).
DR   MIM; 605319; gene.
DR   neXtProt; NX_Q16875; -.
DR   OpenTargets; ENSG00000170525; -.
DR   PharmGKB; PA33213; -.
DR   VEuPathDB; HostDB:ENSG00000170525; -.
DR   eggNOG; KOG0234; Eukaryota.
DR   GeneTree; ENSGT00950000182835; -.
DR   InParanoid; Q16875; -.
DR   OMA; CDEERYT; -.
DR   OrthoDB; 2013830at2759; -.
DR   PhylomeDB; Q16875; -.
DR   TreeFam; TF313541; -.
DR   BioCyc; MetaCyc:HS10144-MON; -.
DR   BRENDA; 2.7.1.105; 2681.
DR   BRENDA; 3.1.3.46; 2681.
DR   PathwayCommons; Q16875; -.
DR   Reactome; R-HSA-9634600; Regulation of glycolysis by fructose 2,6-bisphosphate metabolism.
DR   SABIO-RK; Q16875; -.
DR   SignaLink; Q16875; -.
DR   SIGNOR; Q16875; -.
DR   BioGRID-ORCS; 5209; 14 hits in 1177 CRISPR screens.
DR   ChiTaRS; PFKFB3; human.
DR   EvolutionaryTrace; Q16875; -.
DR   GeneWiki; PFKFB3; -.
DR   GenomeRNAi; 5209; -.
DR   Pharos; Q16875; Tchem.
DR   PRO; PR:Q16875; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q16875; protein.
DR   Bgee; ENSG00000170525; Expressed in pancreatic ductal cell and 192 other tissues.
DR   ExpressionAtlas; Q16875; baseline and differential.
DR   Genevisible; Q16875; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003873; F:6-phosphofructo-2-kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004331; F:fructose-2,6-bisphosphate 2-phosphatase activity; IBA:GO_Central.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0006003; P:fructose 2,6-bisphosphate metabolic process; IBA:GO_Central.
DR   GO; GO:0006000; P:fructose metabolic process; IEA:InterPro.
DR   CDD; cd07067; HP_PGM_like; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.40.50.1240; Phosphoglycerate mutase-like; 1.
DR   InterPro; IPR003094; 6Pfruct_kin.
DR   InterPro; IPR013079; 6Phosfructo_kin.
DR   InterPro; IPR013078; His_Pase_superF_clade-1.
DR   InterPro; IPR029033; His_PPase_superfam.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR001345; PG/BPGM_mutase_AS.
DR   PANTHER; PTHR10606; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; 1.
DR   PANTHER; PTHR10606:SF41; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 3; 1.
DR   Pfam; PF01591; 6PF2K; 1.
DR   Pfam; PF00300; His_Phos_1; 1.
DR   PIRSF; PIRSF000709; 6PFK_2-Ptase; 1.
DR   PRINTS; PR00991; 6PFRUCTKNASE.
DR   SMART; SM00855; PGAM; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF53254; Phosphoglycerate mutase-like; 1.
DR   PROSITE; PS00175; PG_MUTASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Hydrolase; Kinase;
KW   Multifunctional enzyme; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Transferase.
FT   CHAIN           1..520
FT                   /note="6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
FT                   3"
FT                   /id="PRO_0000179968"
FT   REGION          1..245
FT                   /note="6-phosphofructo-2-kinase"
FT   REGION          246..520
FT                   /note="Fructose-2,6-bisphosphatase"
FT   REGION          443..520
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        125
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        155
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        254
FT                   /note="Tele-phosphohistidine intermediate"
FT                   /evidence="ECO:0000269|PubMed:22275052"
FT   ACT_SITE        323
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000269|PubMed:22275052"
FT   BINDING         42..50
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16316985,
FT                   ECO:0000269|PubMed:17499765, ECO:0000269|PubMed:22275052"
FT   BINDING         75
FT                   /ligand="beta-D-fructose 6-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:57634"
FT                   /evidence="ECO:0000269|PubMed:16316985"
FT   BINDING         99
FT                   /ligand="beta-D-fructose 6-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:57634"
FT                   /evidence="ECO:0000269|PubMed:16316985"
FT   BINDING         127
FT                   /ligand="beta-D-fructose 6-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:57634"
FT                   /evidence="ECO:0000269|PubMed:16316985"
FT   BINDING         133
FT                   /ligand="beta-D-fructose 6-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:57634"
FT                   /evidence="ECO:0000269|PubMed:16316985"
FT   BINDING         164..169
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16316985,
FT                   ECO:0000269|PubMed:17499765, ECO:0000269|PubMed:22275052"
FT   BINDING         169
FT                   /ligand="beta-D-fructose 6-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:57634"
FT                   /evidence="ECO:0000269|PubMed:16316985"
FT   BINDING         190
FT                   /ligand="beta-D-fructose 6-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:57634"
FT                   /evidence="ECO:0000269|PubMed:16316985"
FT   BINDING         194
FT                   /ligand="beta-D-fructose 6-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:57634"
FT                   /evidence="ECO:0000269|PubMed:16316985"
FT   BINDING         253
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         260
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         266
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         334
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         345..348
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P07953"
FT   BINDING         348
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         352
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         363
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         389..393
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P07953"
FT   BINDING         389
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000269|PubMed:25849762"
FT   BINDING         393
FT                   /ligand="beta-D-fructose 2,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58579"
FT                   /evidence="ECO:0000250|UniProtKB:P07953"
FT   BINDING         425
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:16316985,
FT                   ECO:0000269|PubMed:17499765, ECO:0000269|PubMed:22275052"
FT   SITE            253
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000269|PubMed:22275052"
FT   SITE            260
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000269|PubMed:22275052"
FT   SITE            388
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000269|PubMed:22275052"
FT   MOD_RES         461
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:12065600,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         463
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         467
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231"
FT   MOD_RES         471
FT                   /note="Phosphothreonine; by PKC"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..26
FT                   /note="MPLELTQSRVQKIWVPVDHRPSLPRS -> MPFRKA (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047165"
FT   VAR_SEQ         1..26
FT                   /note="MPLELTQSRVQKIWVPVDHRPSLPRS -> MGEGGQKEGDSQQAGALPLLCQ
FT                   LDTFSPKATVFGVSINPA (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054549"
FT   VAR_SEQ         506..520
FT                   /note="NMKGSRSSADSSRKH -> PLLGQACLT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10077634"
FT                   /id="VSP_004680"
FT   MUTAGEN         45
FT                   /note="A->G: 20-fold decrease in Km for ATP and 3-fold
FT                   decrease in Km for fructose-6 phsphate."
FT                   /evidence="ECO:0000269|PubMed:17499765"
FT   MUTAGEN         169
FT                   /note="K->R,A,N: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:17499765"
FT   CONFLICT        136
FT                   /note="M -> V (in Ref. 4; AAB99795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        141
FT                   /note="A -> G (in Ref. 5; AAC62000)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..7
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   TURN            9..11
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          14..16
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          36..41
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          43..47
FT                   /evidence="ECO:0007829|PDB:6IBZ"
FT   HELIX           48..61
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          66..70
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           71..78
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          79..81
FT                   /evidence="ECO:0007829|PDB:4D4M"
FT   HELIX           85..88
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           93..116
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          120..126
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           131..143
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          147..154
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           158..168
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   TURN            169..171
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           173..175
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          176..178
FT                   /evidence="ECO:0007829|PDB:6HVJ"
FT   HELIX           180..195
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   TURN            203..209
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          212..216
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   TURN            217..220
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          221..225
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           230..241
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          249..253
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           258..261
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           273..289
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          295..298
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           302..309
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   TURN            310..312
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          315..317
FT                   /evidence="ECO:0007829|PDB:2AXN"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           327..329
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           334..340
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           342..350
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   TURN            352..354
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           363..379
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          381..387
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           389..400
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   TURN            404..406
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           407..409
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          416..423
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   STRAND          426..433
FT                   /evidence="ECO:0007829|PDB:6HVI"
FT   HELIX           442..446
FT                   /evidence="ECO:0007829|PDB:3QPU"
FT   HELIX           455..457
FT                   /evidence="ECO:0007829|PDB:2AXN"
SQ   SEQUENCE   520 AA;  59609 MW;  A7675A4ADC376879 CRC64;
     MPLELTQSRV QKIWVPVDHR PSLPRSCGPK LTNSPTVIVM VGLPARGKTY ISKKLTRYLN
     WIGVPTKVFN VGEYRREAVK QYSSYNFFRP DNEEAMKVRK QCALAALRDV KSYLAKEGGQ
     IAVFDATNTT RERRHMILHF AKENDFKAFF IESVCDDPTV VASNIMEVKI SSPDYKDCNS
     AEAMDDFMKR ISCYEASYQP LDPDKCDRDL SLIKVIDVGR RFLVNRVQDH IQSRIVYYLM
     NIHVQPRTIY LCRHGENEHN LQGRIGGDSG LSSRGKKFAS ALSKFVEEQN LKDLRVWTSQ
     LKSTIQTAEA LRLPYEQWKA LNEIDAGVCE ELTYEEIRDT YPEEYALREQ DKYYYRYPTG
     ESYQDLVQRL EPVIMELERQ ENVLVICHQA VLRCLLAYFL DKSAEEMPYL KCPLHTVLKL
     TPVAYGCRVE SIYLNVESVC THRERSEDAK KGPNPLMRRN SVTPLASPEP TKKPRINSFE
     EHVASTSAAL PSCLPPEVPT QLPGQNMKGS RSSADSSRKH
//
